Minh H N Nguyen, Amanda Memken, Panida Sriaroon, Monica Hajirawala, Jennifer L R Mayer
{"title":"A 12-Step Desensitization Protocol for Calaspargase Pegol-mknl.","authors":"Minh H N Nguyen, Amanda Memken, Panida Sriaroon, Monica Hajirawala, Jennifer L R Mayer","doi":"10.5863/1551-6776-30.1.133","DOIUrl":null,"url":null,"abstract":"<p><p>Asparaginase is a standard treatment for acute lymphoblastic leukemia (ALL) of childhood. As a bacteria-derived enzyme, asparaginase is highly immunogenic, and hypersensitivity reactions (HSRs) routinely lead to drug discontinuation. HSRs remain common even with the introduction of pegaspargase, a PEGylated version of <i>Escherichia coli</i>-derived asparaginase. Asparaginase <i>Erwinia chrysanthemi</i> (recombinant)-rywn (recombinant Erwinia) is an alternative for those with HSRs to pegaspargase. Here, we describe an 11-year-old boy with relapsed ALL who developed HSRs to both pegaspargase and recombinant Erwinia. This is the report of a novel desensitization protocol for calaspargase pegol-mknl (calaspargase) with no adverse events and adequate serum asparaginase activity.</p>","PeriodicalId":37484,"journal":{"name":"Journal of Pediatric Pharmacology and Therapeutics","volume":"30 1","pages":"133-137"},"PeriodicalIF":0.0000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11809534/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pediatric Pharmacology and Therapeutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5863/1551-6776-30.1.133","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/10 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Asparaginase is a standard treatment for acute lymphoblastic leukemia (ALL) of childhood. As a bacteria-derived enzyme, asparaginase is highly immunogenic, and hypersensitivity reactions (HSRs) routinely lead to drug discontinuation. HSRs remain common even with the introduction of pegaspargase, a PEGylated version of Escherichia coli-derived asparaginase. Asparaginase Erwinia chrysanthemi (recombinant)-rywn (recombinant Erwinia) is an alternative for those with HSRs to pegaspargase. Here, we describe an 11-year-old boy with relapsed ALL who developed HSRs to both pegaspargase and recombinant Erwinia. This is the report of a novel desensitization protocol for calaspargase pegol-mknl (calaspargase) with no adverse events and adequate serum asparaginase activity.
期刊介绍：
The Journal of Pediatric Pharmacology and Therapeutics is the official journal of the Pediatric Pharmacy Advocacy Group. JPPT is a peer-reviewed multi disciplinary journal that is devoted to promoting the safe and effective use of medications in infants and children. To this end, the journal publishes practical information for all practitioners who provide care to pediatric patients. Each issue includes review articles, original clinical investigations, case reports, editorials, and other information relevant to pediatric medication therapy. The Journal focuses all work on issues related to the practice of pediatric pharmacology and therapeutics. The scope of content includes pharmacotherapy, extemporaneous compounding, dosing, methods of medication administration, medication error prevention, and legislative issues. The Journal will contain original research, review articles, short subjects, case reports, clinical investigations, editorials, and news from such organizations as the Pediatric Pharmacy Advocacy Group, the FDA, the American Academy of Pediatrics, the American Society of Health-System Pharmacists, and so on.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
